Skip to content

To study the effect of anti-seizure drug named levetiracetam on body weight, blood pressure, blood cholesterol and blood sugar levels in adult patients having seizure disorder treated with levetiracetam.

Metabolic Syndrome in adult persons with Epilepsy treated with Levetiracetam: A Prospective Interventional Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/01/048946
Enrollment
70
Registered
2023-01-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G403- Generalized idiopathic epilepsy and epileptic syndromes

Interventions

Sponsors

Pt BD Sharma PGIMS Rohtak
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients of =18 to = 40 years of age of either gender. 2) Patients with newly diagnosed epilepsy. 3) Patients/LAR willing to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with Body mass index (BMI) = 30 kg/m2. 2) Patients with co-existing Type 2 Diabetes mellitus and/or Hypertension. 3) Patients with dyslipidemia who are already on lipid-lowering agents. 4) Patients on medication that are known to interfere with body weight status, such as antidepressants, corticosteroids, and anti-thyroid drugs. 5) Pregnant patients of epilepsy. 6) Patients with a history of alcohol/ substance abuse. 7) Patients having any personality or psychiatric disorders. 8) Patients having severe physical disability, thyroid, liver, or renal dysfunction.

Design outcomes

Primary

MeasureTime frame
1) Metabolic syndrome and metabolic parameters in the study population.Timepoint: Participants will be assessed initially during enrollment for baseline parameters and will be followed up at 3 and 6 months for assessment of metabolic syndrome and metabolic parameters.

Secondary

MeasureTime frame
A. Health-related quality of life (HRQoL) in the study population. B. Body Mass Index of the study population.Timepoint: Participants will be assessed initially during enrollment for baseline parameters and will be followed up at 3 and 6 months for assessment of Health-related quality of life and Body mass index.

Countries

India

Contacts

Public ContactDr Deepinder Narang

Pt B. D. Sharma PGIMS Rohtak

deepindernarang9@gmail.com9896195685

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026